Lab-on-a-Chip & Microfluidics Patents: Who Leads, Where Gaps Are 2026
- Filing peaked in 2017 at 110 records and the 2021-2024 span shows an 18% decline in complete-year filings, from 73 down to 60.
- The top 5 assignees hold 18.0% of all 1,339 records and the top 10 hold 28.5% — concentrated at the front but with a long tail of single-filing entrants behind them.
- G01N material analysis dominates at 63.0% of records while bioreactor apparatus (C12M, 9.9%) and catalytic processes (B01J, 4.3%) sit far behind, marking the thinner branches.
Filing growth compares 2021 (73 records) with 2024 (60) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,339 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape covers 1,339 published records at the intersection of lab-on-a-chip and microfluidics with semiconductor-style fabrication and clinical-sample handling — devices that borrow wafer, mask-layer and circuit-pattern methods to move biological or clinical specimens through microfluidic channels. The scope spans filings from 2015 through the 2026 data cut-off, so the most recent one to two years are still filling in as publications catch up with filings.
Records were pulled from a search string combining lab-on-a-chip and microfluidic-assay terms with fabrication and specimen-handling terms, then classified against IPC subclasses and grouped by assignee into patent families. The analysis below reads that structure for concentration, technology mix, and the parts of the claim space that remain open.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 1,339 records: how filing activity has moved year over year, and which IPC subclasses carry the claim volume.
Filing trend, 2017-2026
Filings peaked in 2017 at 110 records. Complete-year data puts 2021 at 73 and 2024 at 60, an 18% decline over that span; 2025 and 2026 figures are partial because publication typically lags filing by around 18 months, so they should not yet be read as a continued fall.
Technology composition by IPC subclass
G01N (material analysis and testing) appears in 63.0% of the 1,339 records, well ahead of B01L lab apparatus (33.5%) and C12Q enzyme/DNA measurement (26.2%). Because a single record can carry several IPC codes, these shares sum to more than 100% — they show where claim density sits, not a partition of the field.
Shares are the percentage of the 1,339 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Lab-on-a-Chip & Microfluidics Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about lab-on-a-chip & microfluidics patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited records
Microfluidic assay device (US20230338950A1, Duke University, 2023-10-26)
Described herein is an assay device, comprising a substrate comprising microfluidic geometry, and a reagent layer disposed adjacent to the substrate.The claim scope centres on the substrate-plus-adjacent-reagent-layer architecture, a construction that recurs across the field's most cited assay-device filings.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20040078219A1 | Healthcare networks with biosensors | 1,294 |
| 2 | US20040100376A1 | Healthcare monitoring system | 859 |
| 3 | US20050101841A9 | Healthcare networks with biosensors | 612 |
| 4 | US20090325276A1 | Integrated microfluidic assay devices and methods | 358 |
| 5 | US20090148933A1 | Integrated nucleic acid assays | 344 |
| 6 | US9931040B2 | Applications of hyperspectral laser speckle imaging | 293 |
| 7 | US20180214025A1 | Applications of hyperspectral laser speckle imaging | 263 |
| 8 | US20060046313A1 | Cellular analysis using Raman surface scanning | 242 |
| 9 | US20180095067A1 | Devices and methods for sample analysis | 205 |
| 10 | US20110053289A1 | Assay Device and Method | 199 |
Citation counts favour older records simply because they have had longer to accumulate them inside this corpus — treat them as a signal of influence on later filings, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Four readings of the same dataset, each aimed at a different question a filer or licensing team needs answered before committing resources.
The front of the field is concentrated, the rest is a long tail
The top 5 assignees combined hold 18.0% of all 1,339 records and the top 10 hold 28.5%. That leaves the majority of records spread across the remaining ranked companies and unranked filers, which is where freedom-to-operate searches typically turn up single-filing entrants rather than repeat blockers.
Volume is easing back from its 2017 peak, not accelerating
Filings peaked at 110 in 2017. The most recent complete comparison, 2021 against 2024, shows a decline of 18%, from 73 to 60 records. Read that as a maturing filing pace rather than as an active slowdown — 2025 and 2026 figures are still incomplete because of publication lag.
Material analysis claims occupy the most contested ground
G01N covers material analysis and testing and appears on 63.0% of the 1,339 records — the densest single subclass in scope. B01L lab apparatus (33.5%) and C12Q enzyme/DNA measurement (26.2%) follow. High density here signals occupied claim space, not that the underlying technology is settled.
US filing leads, but PCT and EPO routes carry real weight
The United States receives the largest single share of filings at 376, with Europe (EPO) at 243 and the WIPO PCT route at 216. Australia, Canada and India each sit lower, at 76, 62 and 62 respectively, which is a useful check when deciding where a freedom-to-operate search needs to go deepest.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lab-on-a-chip & microfluidics patent landscape, with the prior art for and against each one.
Who holds the claim space, and what is still open
The ranked leaders sit well ahead of a long tail, but recent-year filing activity among the largest names has gone quiet — worth checking against your own monitoring before assuming continued dominance.
A single university leads the ranking outright
The top-ranked assignee holds 70 records, more than double the fifth-place total of 32 and nearly triple the tenth-place total of 25. That gap between first place and the rest of the top ten is the clearest sign of where institutional filing effort has concentrated over the scope period.
The drop from fifth to tenth place is gradual, not a cliff
Fifth place holds 32 records and tenth place holds 25 — a modest decline rather than a sharp fall-off. That gradual slope suggests several mid-tier assignees are filing at comparable rates, making this tier worth watching for consolidation or new entrants rather than assuming it is settled.
Co-filing is limited and concentrated among a few partners
Only 10 co-assignee pairs appear in the dataset, with the strongest pairing recording 12 joint filings. Co-filing activity clusters around a small number of academic-industry or academic-inventor relationships rather than being spread broadly across the ranked leaders.
| Assignee | Recent year | YoY |
|---|---|---|
| The Regents of the University of California | 0 | — |
| The University of British Columbia | 0 | — |
| Precision Company (Precision Biosciences) | 0 | — |
| Abbott Laboratories | 0 | — |
| President and Fellows of Harvard College | 0 | — |
| Becton, Dickinson and Company | 0 | — |
| Quantum IP Holdings Pty Ltd | 0 | -100% |
| Case Western Reserve University | 0 | — |
Where to take this from here
The dataset points to a field with a concentrated front rank, a dense analytical core, and several under-filed branches. Turning that into a filing or licensing decision means going deeper on the specific claims.
Run a freedom-to-operate check on the dense subclasses
G01N, B01L and C12Q carry the bulk of claim density in this dataset. Before drafting new claims in these areas, check the specific claim language of the leading assignees' families rather than relying on subclass share alone.
Explore prior art in EurekaWatch the mid-tier for consolidation
The gradual slope between fifth and tenth place suggests no single mid-tier assignee has pulled decisively ahead. Track filing activity here over the next few publication cycles to see whether that changes.
Track assignee activity in EurekaTest claims in the under-claimed branches
Catalytic microreactor chemistry and bioreactor-integrated apparatus show thinner claim density than the analytical core. A well-drafted first claim in these branches may face less crowded prior art.
Draft and search claims in EurekaCommon questions about this landscape
The ranking in this dataset covers 100 companies and is led by a single assignee with 70 records, well ahead of fifth place at 32 and tenth place at 25. The top 5 assignees combined account for 18.0% of all 1,339 records in scope, and the top 10 account for 28.5%. Beyond that front group, filing activity spreads across a long tail of companies and academic institutions with far fewer records each, so a freedom-to-operate search should not assume the field is controlled by a handful of firms.
Filing activity peaked in 2017 at 110 records and has eased since. The most recent complete-year comparison, 2021 against 2024, shows a decline of 18%, from 73 records down to 60. Figures for 2025 and 2026 are still partial because publication typically lags filing by around 18 months, so they understate real filing activity and should not be read as evidence of a continued drop.
Material analysis and testing, classified under IPC subclass G01N, appears on 63.0% of the 1,339 records in scope, making it the single densest area. Lab apparatus (B01L) follows at 33.5% and enzyme/DNA measurement (C12Q) at 26.2%. Because records can carry multiple IPC classes, these figures overlap rather than partition the field, but the ranking is a reliable guide to where claim space is most occupied.
Relative to the dense analytical core, subclasses like C12M (bioreactors and enzyme apparatus, 9.9% of records), C07K (peptides and proteins, 7.2%), and B01J (chemical and physical catalysis processes, 4.3%) carry noticeably thinner claim density. That does not guarantee an easy filing, but it does suggest these branches have seen less claim activity relative to their potential scope, and are worth a closer prior-art check before assuming they are crowded.
US20230338950A1, assigned to Duke University and published 2023-10-26, describes a microfluidic assay device built from a substrate with microfluidic geometry and a reagent layer disposed adjacent to that substrate. The claim scope centres on that substrate-plus-adjacent-reagent-layer construction, a design pattern that recurs across several of the field's most cited assay-device filings. Anyone designing a similar assay device should check the specific claim boundaries of this family before assuming a different reagent-layer placement clears it.
Research Lab-on-a-Chip & Microfluidics Patent Landscape in depth with Eureka
Go past this page: query the whole lab-on-a-chip & microfluidics patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.